Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer

Breast Cancer

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial

Ann Oncol

Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, Ribi K, Ruddy KJ, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Partridge AH, International Breast Cancer Study Group, POSITIVE Trial Consortium

doi: 10.1016/j.annonc.2026.05.699

Breast Cancer

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database

Eur J Cancer

Aristei C, Tomatis M, Ponti A, Marotti L, Battisti NML, Leung Cheung K, Hartmann OJ, Rubio IT, Santini D, Sardanelli F, Senkus E, van Dam P, Curigliano G, Eusoma Working Group

doi: 10.1016/j.ejca.2026.116259

Breast Cancer

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

Lancet Oncol

Villacampa G, Pascual T, Tarantino P, Cortés J, Perez-García J, Llombart-Cussac A, Conte P, Mancino M, Guarneri V, Dieci MV, Waks AG, Schettini F, Brasó-Maristany F, Griguolo G, de Castro BA, Reboredo C, Antolín S, Bueno-Muiño C, Echavarría I, López-Tarruella S, Massarrah T, Del Monte-Millán M, Martín M, Buckingham W, Parker JS, Vivancos A, Polyak K, Filho OM, Wolff AC, DeMichele A, Tung NM, Perou CM, Paré L, Villagrasa P, Prat A, Tolaney SM

doi: 10.1016/S1470-2045(25)00276-1

Lung, Respiratory and Thoracic Cancer

European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy

Lung Cancer

Lula LJ, Costa R, Huang L, Rushwan A, Domjan M, Franssen AJPM, Weedle R, Trabalza Marinucci B, Barreda CF, Jasovic C, Whooley J, Matache RS, Özgür EG, Ryan R, Young V, Tahiri M, Fernandes P, Rendina EA, Bekiroglu N, de Loos ER, Jimenez M, Savu C, Bolca C, Stupnik T, Fitzmaurice GJ, D'Andrilli A, Brunelli A, Petersen RH

doi: 10.1016/j.lungcan.2026.109410

Breast Cancer

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Ann Oncol

Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025

doi: 10.1016/j.annonc.2025.09.007

Breast Cancer

Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study

Eur J Cancer

Louis FM, der Voort AV, Egeler MD, Ramshorst MSV, Mandjes IA, Kemper I, Agterof MJ, der Steeg WAV, Heijns JB, Bekkum MLV, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Peeters MTV, Mann RM, de Poll-Franse LVV, Sonke GS, Dutch Breast Cancer Research Group (BOOG)

doi: 10.1016/j.ejca.2026.116882

Breast Cancer

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer

Ann Oncol

Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Rubovszky G, Tondini C, Ciruelos EM, Gomez HL, Bonnefoi HR, Burstein HJ, Chini C, Puglisi F, Spazzapan S, Bernardo A, Climent MA, Bellet M, Ruhstaller T, Bermejo B, Chia SKL, Martino S, Geyer CE Jr, Goetz MP, Ingle JN, Stearns V, Davidson NE, Le Du F, Müller B, Coleman RE, Loibl S, Winer EP, Ruepp B, Loi S, Láng I, Coates AS, Gelber RD, Goldhirsch A, Regan MM, International Breast Cancer Study Group, SOFT and TEXT Investigators

doi: 10.1016/j.annonc.2026.05.704

Breast Cancer

Aprepitant use during chemotherapy and association with survival in women with early breast cancer

J Natl Cancer Inst

Botteri E, Hjorth S, Conforti F, Bagnardi V, Andreassen BK, Støer NC, Bhargava S, Ursin G, Gandini S, Sloan EK, Chang A

doi: 10.1093/jnci/djaf178

Breast CancerGynecologic Cancer

The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled Trial

Psychooncology

Gaignard ME, Martin D, Stanic J, Hilfiker R, Bodmer A, Ljuslin M, Zaman K, Labidi-Galy I, Sarivalasis A, Carlson LE, Peters S, Dietrich PY, Eicher M, Bondolfi G, Jermann F

doi: 10.1002/pon.70334

Related content

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database

HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis

European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer

Aprepitant use during chemotherapy and association with survival in women with early breast cancer

The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled Trial